Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington. more
Time Frame | IMNM | Sector | S&P500 |
---|---|---|---|
1-Week Return | -8.38% | -2.27% | -0.57% |
1-Month Return | 8.54% | -3.96% | 1.21% |
3-Month Return | -21.23% | -9.7% | 7.57% |
6-Month Return | -21.57% | -3.37% | 11.45% |
1-Year Return | 71.39% | 3.71% | 28.48% |
3-Year Return | -24.85% | 3.8% | 29.52% |
5-Year Return | -6.47% | 39.78% | 90.66% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | 6.63M | 14.02M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":47.27,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 615.00K | 755.00K | 755.00K | 631.00K | 22.93M | [{"date":"2019-12-31","value":2.68,"profit":true},{"date":"2020-12-31","value":3.29,"profit":true},{"date":"2021-12-31","value":3.29,"profit":true},{"date":"2022-12-31","value":2.75,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | (615.00K) | (755.00K) | (755.00K) | (631.00K) | (8.91M) | [{"date":"2019-12-31","value":-61500000,"profit":false},{"date":"2020-12-31","value":-75500000,"profit":false},{"date":"2021-12-31","value":-75500000,"profit":false},{"date":"2022-12-31","value":-63100000,"profit":false},{"date":"2023-12-31","value":-890700000,"profit":false}] |
Gross Margin | (Infinity%) | (Infinity%) | (Infinity%) | (9.52%) | (63.54%) | [{"date":"2019-12-31","value":null,"profit":false},{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":-9.52,"profit":false},{"date":"2023-12-31","value":-63.54,"profit":false}] |
Operating Expenses | 10.35M | 12.26M | 25.20M | 36.90M | 122.82M | [{"date":"2019-12-31","value":8.43,"profit":true},{"date":"2020-12-31","value":9.98,"profit":true},{"date":"2021-12-31","value":20.52,"profit":true},{"date":"2022-12-31","value":30.04,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (10.35M) | (12.26M) | (25.20M) | (36.90M) | (109.53M) | [{"date":"2019-12-31","value":-1034800000,"profit":false},{"date":"2020-12-31","value":-1226100000,"profit":false},{"date":"2021-12-31","value":-2520400000,"profit":false},{"date":"2022-12-31","value":-3690100000,"profit":false},{"date":"2023-12-31","value":-10953000000,"profit":false}] |
Total Non-Operating Income/Expense | (192.00K) | (5.61M) | 483.00K | 10.00K | 5.45M | [{"date":"2019-12-31","value":-3.52,"profit":false},{"date":"2020-12-31","value":-103.05,"profit":false},{"date":"2021-12-31","value":8.87,"profit":true},{"date":"2022-12-31","value":0.18,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (10.44M) | (17.84M) | (24.71M) | (36.90M) | (106.81M) | [{"date":"2019-12-31","value":-1044400000,"profit":false},{"date":"2020-12-31","value":-1783700000,"profit":false},{"date":"2021-12-31","value":-2471100000,"profit":false},{"date":"2022-12-31","value":-3689600000,"profit":false},{"date":"2023-12-31","value":-10680600000,"profit":false}] |
Income Taxes | 106.00K | (717.00K) | (242.00K) | 617.00K | 560.11K | [{"date":"2019-12-31","value":17.18,"profit":true},{"date":"2020-12-31","value":-116.21,"profit":false},{"date":"2021-12-31","value":-39.22,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":90.78,"profit":true}] |
Income After Taxes | (10.55M) | (17.12M) | (24.47M) | (37.51M) | (107.37M) | [{"date":"2019-12-31","value":-1055000000,"profit":false},{"date":"2020-12-31","value":-1712000000,"profit":false},{"date":"2021-12-31","value":-2446900000,"profit":false},{"date":"2022-12-31","value":-3751300000,"profit":false},{"date":"2023-12-31","value":-10736610500,"profit":false}] |
Income From Continuous Operations | (10.44M) | (17.84M) | (24.71M) | (36.90M) | (106.81M) | [{"date":"2019-12-31","value":-1044400000,"profit":false},{"date":"2020-12-31","value":-1783700000,"profit":false},{"date":"2021-12-31","value":-2471100000,"profit":false},{"date":"2022-12-31","value":-3689600000,"profit":false},{"date":"2023-12-31","value":-10680600000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (10.55M) | (17.12M) | (24.47M) | (37.51M) | (106.81M) | [{"date":"2019-12-31","value":-1055000000,"profit":false},{"date":"2020-12-31","value":-1712000000,"profit":false},{"date":"2021-12-31","value":-2446900000,"profit":false},{"date":"2022-12-31","value":-3751300000,"profit":false},{"date":"2023-12-31","value":-10680600000,"profit":false}] |
EPS (Diluted) | - | (8.50) | (2.16) | (3.09) | (5.39) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-850,"profit":false},{"date":"2021-12-31","value":-216,"profit":false},{"date":"2022-12-31","value":-309,"profit":false},{"date":"2023-12-31","value":-539,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
IMNM | |
---|---|
Cash Ratio | 6.07 |
Current Ratio | 6.17 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
IMNM | |
---|---|
ROA (LTM) | -39.89% |
ROE (LTM) | -276.36% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
IMNM | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.16 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.84 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
IMNM | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 77.52 |
P/B | 3.65 |
Price/FCF | NM |
EV/R | 54.08 |
EV/Ebitda | NM |
Immunome Inc (IMNM) share price today is $12.58
Yes, Indians can buy shares of Immunome Inc (IMNM) on Vested. To buy Immunome Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in IMNM stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Immunome Inc (IMNM) via the Vested app. You can start investing in Immunome Inc (IMNM) with a minimum investment of $1.
You can invest in shares of Immunome Inc (IMNM) via Vested in three simple steps:
The 52-week high price of Immunome Inc (IMNM) is $30.96. The 52-week low price of Immunome Inc (IMNM) is $7.48.
The price-to-earnings (P/E) ratio of Immunome Inc (IMNM) is
The price-to-book (P/B) ratio of Immunome Inc (IMNM) is 3.65
The dividend yield of Immunome Inc (IMNM) is 0.00%
The market capitalization of Immunome Inc (IMNM) is $876.33M
The stock symbol (or ticker) of Immunome Inc is IMNM